Roseltide rT7 is a disulfide-rich, anionic, and cell-penetrating peptide that inhibits proteasomal degradation

  1. James P. Tam2
  1. School of Biological Sciences, Nanyang Technological University, Singapore 637551
  2. §Department of Biological Sciences, National University of Singapore, Singapore 117543
  1. 2 To whom correspondence should be addressed: School of Biological Sciences, Nanyang Technological University, 60 Nanyang Dr., Singapore 637551. E-mail: JPTam{at}ntu.edu.sg.
  1. 1 These authors contributed equally to this work.

  2. Edited by Joseph M. Jez

Abstract

Disulfide-rich plant peptides with molecular masses of 2–6 kDa represent an expanding class of peptidyl-type natural products with diverse functions. They are structurally compact, hyperstable, and underexplored as cell-penetrating agents that inhibit intracellular functions. Here, we report the discovery of an anionic, 34-residue peptide, the disulfide-rich roseltide rT7 from Hibiscus sabdariffa (of the Malvaceae family) that penetrates cells and inhibits their proteasomal activities. Combined proteomics and NMR spectroscopy revealed that roseltide rT7 is a cystine-knotted, six-cysteine hevein-like cysteine-rich peptide. A pair-wise comparison indicated that roseltide rT7 is >100-fold more stable against protease degradation than its S-alkylated analog. Confocal microscopy studies and cell-based assays disclosed that after roseltide rT7 penetrates cells, it causes accumulation of ubiquitinated proteins, inhibits human 20S proteasomes, reduces tumor necrosis factor-induced IκBα degradation, and decreases expression levels of intercellular adhesion molecule-1. Structure-activity studies revealed that roseltide rT7 uses a canonical substrate-binding mechanism for proteasomal inhibition enabled by an IIML motif embedded in its proline-rich and exceptionally long intercysteine loop 4. Taken together, our results provide mechanistic insights into a novel disulfide-rich, anionic, and cell-penetrating peptide, representing a potential lead for further development as a proteasomal inhibitor in anti-cancer or anti-inflammatory therapies.

Footnotes

  • This work was supported in part by Nanyang Technological University Internal Funding–Synzymes and Natural Products (SYNC) and AcRF Tier 3 funding Grant MOE2016-T3-1-003. The authors declare that they have no conflicts of interest with the contents of this article.

  • This article contains Tables S1 and S2 and Figs. S1–S28.

  • The atomic coordinates and structure factors (code 6KLM) have been deposited in the Protein Data Bank (http://wwpdb.org/).

  • The NMR chemical shift data of this paper are available from the Biological Magnetic Resonance Data Bank under BMRB accession number 36133.

  • Received August 29, 2019.
  • Revision received November 2, 2019.

Published under exclusive license by The American Society for Biochemistry and Molecular Biology, Inc.

Table of Contents

Submit your work to JBC.

You'll be in good company.